# The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE

> **NCT03635788** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 456 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Standard of Care (SOC) Oral ART
- **DRUG:** Oral RPV
- **DRUG:** Oral CAB
- **DRUG:** RPV-LA Loading Dose
- **DRUG:** CAB-LA Loading Dose
- **DRUG:** RPV-LA Maintenance Dose
- **DRUG:** CAB-LA Maintenance Dose

## Key facts

- **NCT ID:** NCT03635788
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-03-28
- **Primary completion:** 2024-02-12
- **Final completion:** 2026-08-30
- **Target enrollment:** 456 (ACTUAL)
- **Last updated:** 2025-09-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03635788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03635788, "The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03635788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*